A Phase 3 interventional study of Specific Lp(a) apheresis in Atherosclerosis, Coronary Disease and Carotid Artery Diseases, sponsored by Russian Cardiology Research and Production Center. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-05-12.
Sponsored by Russian Cardiology Research and Production Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Atherosclerosis with a site in Russian Federation — 5 open to participants now, 5 under way, none of them phase 3. Atherosclerosis · Russian Federation.
Among the 35 studies in Atherosclerosis with a site in Russian Federation, this one is the 26th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2009, is one of 8 in phase 3, and was the 15th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →5 of the 35 studies in Atherosclerosis with a site in Russian Federation are open now. Recruiting first, the newest first:
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology · Sites in Russian Federation
Ages 50–80
Ryazan State Medical University · Sites in Russian Federation
Ages 18+
Center for Strategic Planning, of the Federal Medical and Biological Agency · Sites in Russian Federation
Ages 18+
Meshalkin Research Institute of Pathology of Circulation · Sites in Russian Federation
Ages 45–80
Russian Cardiology Research and Production Center · Sites in Russian Federation
Ages 7–80
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 200 across the 27 interventional studies, 1,000 across the 8 observational. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 35 have an industry lead sponsor. The 10 most frequent:
Russian Cardiology Research and Production Center is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Russian Cardiology Research and Production Center has 3 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Atherosclerosis with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate whether specific lipoprotein(a) apheresis on the top of optimal medical therapy could affect atherosclerotic disease burden in coronary and carotid arteries of coronary heart disease patients with elevated Lp(a) levels.
Following the hypothesis that if Lp(a) excess has a pathogenic role in atherogenesis, then specific elimination of circulating Lp(a) should affect plaque growth and stability, we evaluated the efficacy of Lp(a) apheresis on changes in coronary plaque volume and composition and carotid intima-media thickness in patients with CHD on the background of optimal medical treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Specific Lp(a) apheresis was performed with "Lp(a) Lipopak" immunosorbent columns ("POCARD" Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD.
Procedure: Specific Lp(a) apheresis
Standard medical therapy in accordance with the recommendations for secondary prevention of CHD
Specific Lp(a) apheresis procedures were carried out weekly with "Lp(a) Lipopak" columns (POCARD Ltd., Moscow, Russia) according to the standard protocol
Also known as: "Lp(a) Lipopak" immunoadsorption columns
Change in Percent Diameter Stenosis
The absolute change from baseline to 18 months in mean percent diameter stenosis, determined by quantitative coronary angiography (QCA) as the narrowest lesion in each segment and calculated as: ((reference diameter-minimal lumen diameter (MLD))/reference diameter)x100.
Time frame: From Baseline to End of Study (Week 72)
Change in mean carotid intima-media thickness (IMT)
Change from baseline in mean carotid IMT, as measured by duplex ultrasonography of common carotid arteries after 9 and 18 months.
Time frame: From Baseline to Week 36 (9 months) and to Week 72 (18 months)
Numbers of Coronary segments Showing Regression
Clinically relevant regression or progression was defined as a change from baseline to follow up of ≥10% for percent diameter stenosis
Time frame: From baseline to End of study (Week 72)
Number of Carotid Segments showing Regression
Carotid IMT progression criterion for the 18 months of treatment was considered as growth rate of 0.02 mm (0.015 mm/yr). No changes or reduction in carotid IMT ≥ 0,02 mm served as criterion of stabilization and regression of carotid atherosclerosis, respectively.
Time frame: From Baseline to End of study (Week 72)
Change in total atheroma volume (TAV) from baseline to 18 months post-therapy
TAV at baseline - TAV at Week 72 assessed by intravascular ultrasound (IVUS) imaging of a targeted coronary artery
Time frame: From Baseline to Week 72
Change in absolute volumes of plaque components
Mean change in absolute volumes of plaque components: fibrotic, fibrofatty, necrotic core or dense calcium, assessed by radiofrequency intravascular ultrasonographic (IVUS) imaging at baseline and 18 months post-therapy
Time frame: From Baseline to Week 72
Change in relative amount of plaque components
Mean change in relative amounts of plaque components: fibrotic, fibrofatty, necrotic core or dense calcium, assessed by radiofrequency intravascular ultrasonographic (IVUS) imaging at baseline and 18 months post-therapy
Time frame: From baseline to Week 72
Numbers of Coronary Plaques Showing Regression
Regression was defined as decrease in TAV for all anatomically comparable cross sectional areas of targeted coronary artery from baseline of ≥ 0,1 mm cubed
Time frame: From baseline to End of study (Week 72)
Acute change in Lp(a) level
Difference in Lp(a) concentration before and after specific Lp(a) apheresis procedure calculated as the mean of all measurements
Time frame: Once a week over 72 week period of active treatment
Change in quality of life (QOL)
To evaluate the impact of the specific Lp(a) removal therapy on the quality of life using Seattle Angina Questionnaire (SAQ) and Exercise stress test as compared with standard guideline-driven medical therapy of CHD patients
Time frame: from baseline to week 72
Total Cholesterol (TC) Serum Level
Mean changes in TC level over the 18-month study period
Time frame: From Baseline to Week 4, 36, 72
Lipoprotein(a) (Lp(a)) serum levels
Mean changes in Lp(a) level over the 18-month study period
Time frame: From Baseline to Week 4, 36, 72
Low-density lipoprotein cholesterol (LDL-C) serum Level
Mean changes in LDL-C level over the 18-month study period
Time frame: From Baseline to Week 4, 36, 72
Change in corrected LDL-C (LDL-C corr) Serum level
Since all included patients had high Lp(a) levels, to avoid overestimation of LDL-C fraction estimated LDL-C levels were corrected for cholesterol derived from Lp(a). Corrected LDL-C (LDL-C corr) was calculated using Dahlen's modification of the Friedewald formula: LDL-C corr = TC - (HDL-C) - (TG / 2.2) - (0.3 x Lp(a) / 38.7). For values in mmol/L, Lp(a) in mg/dL
Time frame: From Baseline to Week 4, 36, 72
Change in triglycerides (TG) serum Level
Mean changes in TG level over the 18-month study period
Time frame: From Baseline to Week 4, 36, 72
Change in high-density lipoprotein cholesterol (HDL-C) serum level
Mean changes in HDL-C level over the 18-month study period
Time frame: From Baseline to Week 4, 36, 72
Change in hemoglobin level
Time frame: From Baseline to Week 4, 36, 72
Change in creatinine level
Time frame: From Baseline to Week 4, 36, 72
Change in creatine kinase (CK) level
Time frame: From Baseline to Week 4, 36, 72
Change in alanine transaminase (ALT) level
Time frame: From Baseline to Week 4, 36, 72
Change in aspartate transaminase (AST) level
Time frame: From Baseline to Week 4, 36, 72
The record gives a start of Sep 2009, a primary completion of Mar 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Russian Cardiology Research and Production Center